Cellectis SA
CLLS3.240USD
+0.110+3.51%
Market hours （ET）Quotes delayed by 15 min
234.33MMarket Cap
LossP/E TTM
More Details of Cellectis SA Company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA Info
Ticker SymbolCLLS
Company nameCellectis SA
IPO dateFeb 06, 2007
CEODr. David Sourdive, Ph.D.
Number of employees224
Security typeDepository Receipt
Fiscal year-endFeb 06
Address8, rue de la Croix Jarry
CityPARIS
Stock exchangeNASDAQ Global Market Consolidated
CountryFrance
Postal code75013
Phone33181691600
Websitehttps://www.cellectis.com/
Ticker SymbolCLLS
IPO dateFeb 06, 2007
CEODr. David Sourdive, Ph.D.
Company Executives of Cellectis SA
Name
Name/Position
Position
Shareholding
Change
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: 20 hours ago
Updated: 20 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
6.52%
B Group, Inc.
4.50%
UBS Asset Management (Americas) LLC
2.59%
UBS Asset Management Switzerland AG
1.99%
UBS Asset Management (Switzerland)
1.80%
Other
82.59%
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
6.52%
B Group, Inc.
4.50%
UBS Asset Management (Americas) LLC
2.59%
UBS Asset Management Switzerland AG
1.99%
UBS Asset Management (Switzerland)
1.80%
Other
82.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
11.60%
Hedge Fund
6.57%
Investment Advisor/Hedge Fund
0.40%
Research Firm
0.19%
Other
81.24%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
72
13.58M
18.77%
-9.58M
2025Q2
78
18.10M
25.03%
-2.47M
2025Q1
83
18.44M
25.50%
-2.58M
2024Q4
88
17.72M
24.57%
+1.29M
2024Q3
106
16.31M
22.62%
-2.61M
2024Q2
105
14.76M
20.47%
-2.65M
2024Q1
113
14.77M
20.56%
-2.69M
2023Q4
124
14.69M
20.46%
-8.13M
2023Q3
142
13.62M
24.51%
-10.91M
2023Q2
155
16.13M
29.02%
-9.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Long Focus Capital Management LLC
4.72M
6.52%
--
--
Jun 30, 2025
B Group, Inc.
3.26M
4.5%
--
--
Jun 30, 2025
UBS Asset Management (Americas) LLC
1.87M
2.59%
+27.88K
+1.51%
Jun 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
UBS Asset Management (Switzerland)
1.30M
1.8%
-1.57M
-54.65%
Jun 30, 2025
Macquarie Investment Management
226.88K
0.31%
--
--
Jun 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jan 31, 2025
LPL Financial LLC
85.66K
0.12%
+915.00
+1.08%
Jun 30, 2025
Morgan Stanley & Co. International Plc
73.19K
0.1%
+6.00K
+8.93%
Jun 30, 2025
AllianceBernstein L.P.
54.64K
0.08%
+32.83K
+150.56%
Jun 30, 2024
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Avantis International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
